Search

Your search keyword '"Francesco Atzori"' showing total 2 results
Start Over Author "Francesco Atzori" Journal journal of translational medicine
2 results on '"Francesco Atzori"'

1. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Author

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Daniele Santini, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Pasquale Rescigno, and Sebastiano Buti

Subjects
Metastatic renal cell carcinoma, Nephrectomy, Immunotherapy, Nivolumab, Prognostic, Meet URO score, Medicine
Abstract

Abstract Background Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines and targeted therapy, but it is still unclear in the immunotherapy era. Methods We investigated the Meet-URO-15 study dataset of 571 pretreated mRCC patients receiving nivolumab as second or further lines about the prognostic role of the previous nephrectomy (received in either the localized or metastatic setting) in the overall population and according to the Meet-URO score groups. Results Patients who underwent nephrectomy showed a significantly reduced risk of death (HR 0.44, 95% CI 0.32–0.60, p

Published
2022
Full Text
View/download PDF

2. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

Author

Grazia Palomba, Mario Budroni, Giuseppe Palmieri, Antonio Cossu, MariaNeve Ombra, Valeria Pusceddu, Francesca Notari, MariaCristina Sini, Francesco Atzori, Bruno Massidda, MariaTeresa Ionta, and B. Frau

Subjects
Adult, Oncology, medicine.medical_specialty, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Platinum-based chemoterapy, Bioinformatics, General Biochemistry, Genetics and Molecular Biology, Loss of heterozygosity, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genotype, Biomarkers, Tumor, Humans, Medicine, Prospective cohort study, Aged, Medicine(all), Chemotherapy, Genetic polymorphism, Polymorphism, Genetic, T4 breast cancer, Biochemistry, Genetics and Molecular Biology(all), business.industry, Proportional hazards model, Research, General Medicine, Middle Aged, Prognosis, Endonucleases, medicine.disease, 3. Good health, DNA-Binding Proteins, Regimen, Female, Cisplatin, ERCC1, business
Abstract

Background: Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1) gene have been involved in the prognosis of various cancers. In the present study, we evaluated the prognostic role of the two most common ERCC1 polymorphisms in patients with T4 breast cancer receiving platinum-based chemotherapy. Methods: A total of 47 patients with T4 breast cancer undergoing treatment with a platinum-based regimen were collected and followed up (median 159 months; range, 42–239 months). ERCC1 C8092A (rs3212986) and T19007C (rs11615) polymorphisms were genotyped, using an automated sequencing approach. The same series was screened for BRCA1/2 mutations by DHPLC analysis and DNA sequencing. Results: Among the tested patients, 16 (34%) and 25 (53%) presented the 8092A (homo-zygosity A/A or heterozygosity A/C) and the 19007C (homozygosity C/C or heterozygosity C/T) genotypes, respectively. The 8092A and 19007C genotypes in ERCC1 were significantly associated with overall survival in T4 breast cancer patients treated with chemotherapy containing platinum (p-values = 0.036 and 0.004, respectively). Univariate and multivariate Cox regression analyses showed that combination of 8092A and 19007C genotypes acts as a significant prognostic factor in women with T4 breast cancer receiving platinum-based chemotherapy (p-values = 0.022 and 0.049, respectively). Two (4.3%) out of 47 cases were found to carry BRCA1/2 mutations; they presented the highest overall survival rates into the series. Conclusions: The ERCC1 8092A and 19007C genotypes or their combination may predict a favorable prognosis in T4 breast cancer patients undergoing a platinum-based treatment. Further large-scale, prospective studies are needed to validate our findings.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results